Your browser doesn't support javascript.
loading
PSMF1 variants cause a phenotypic spectrum from early-onset Parkinson's disease to perinatal lethality by disrupting mitochondrial pathways.
Magrinelli, Francesca; Tesson, Christelle; Angelova, Plamena R; Salazar-Villacorta, Ainara; Rodriguez, Jose A; Scardamaglia, Annarita; Chung, Brian Hon-Yin; Jaconelli, Matthew; Vona, Barbara; Esteras, Noemi; Kwong, Anna Ka-Yee; Courtin, Thomas; Maroofian, Reza; Alavi, Shahryar; Nirujogi, Raja; Severino, Mariasavina; Lewis, Patrick A; Efthymiou, Stephanie; O'Callaghan, Benjamin; Buchert, Rebecca; Sofan, Linda; Lis, Pawel; Pinon, Chloé; Breedveld, Guido J; Chui, Martin Man-Chun; Murphy, David; Pitz, Vanessa; Makarious, Mary B; Cassar, Marlene; Hassan, Bassem A; Iftikhar, Sana; Rocca, Clarissa; Bauer, Peter; Tinazzi, Michele; Svetel, Marina; Samanci, Bedia; Hanagasi, Hasmet A; Bilgiç, Basar; Obeso, José A; Kurtis, Monica M; Cogan, Guillaume; Basak, Ayse Nazli; Kiziltan, Günes; Gül, Tugçe; Yalçin, Gül; Elibol, Bülent; Barisic, Nina; Ng, Earny Wei-Sen; Fan, Sze-Shing; Hershkovitz, Tova.
Afiliação
  • Magrinelli F; Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom.
  • Tesson C; Institut du Cerveau et de la Moelle épinière, ICM, Inserm, CNRS, Sorbonne Université, Paris, France.
  • Angelova PR; Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom.
  • Salazar-Villacorta A; Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom.
  • Rodriguez JA; Laboratory of Apoptosis and Cancer Biology, The Rockefeller University, New York, NY, USA.
  • Scardamaglia A; Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom.
  • Chung BH; Department of Paediatrics and Adolescent Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
  • Jaconelli M; Hong Kong Genome Institute, Hong Kong SAR, China.
  • Vona B; Medical Research Council (MRC) Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dundee, United Kingdom.
  • Esteras N; Institute of Human Genetics, University Medical Center Göttingen, Göttingen, Germany.
  • Kwong AK; Institute for Auditory Neuroscience and Inner Ear Lab, University Medical Center Göttingen, Göttingen, Germany.
  • Courtin T; Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom.
  • Maroofian R; Neurochemistry Research Institute, Department of Biochemistry and Molecular Biology, School of Medicine, Complutense University of Madrid, Madrid, Spain.
  • Alavi S; CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, Madrid, Spain.
  • Nirujogi R; Department of Paediatrics and Adolescent Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
  • Severino M; Institut du Cerveau et de la Moelle épinière, ICM, Inserm, CNRS, Sorbonne Université, Paris, France.
  • Lewis PA; Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom.
  • Efthymiou S; Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom.
  • O'Callaghan B; Medical Research Council (MRC) Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dundee, United Kingdom.
  • Buchert R; Neuroradiology Unit, IRCCS Istituto Giannina Gaslini, Genova, Italy.
  • Sofan L; Royal Veterinary College, London, United Kingdom.
  • Lis P; Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom.
  • Pinon C; Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom.
  • Breedveld GJ; Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom.
  • Chui MM; Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany.
  • Murphy D; Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany.
  • Pitz V; Medical Research Council (MRC) Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dundee, United Kingdom.
  • Makarious MB; Institut du Cerveau et de la Moelle épinière, ICM, Inserm, CNRS, Sorbonne Université, Paris, France.
  • Cassar M; Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Hassan BA; Department of Paediatrics and Adolescent Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
  • Iftikhar S; Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom.
  • Rocca C; Integrative Neurogenomics Unit, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.
  • Bauer P; Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.
  • Tinazzi M; Institut du Cerveau et de la Moelle épinière, ICM, Inserm, CNRS, Sorbonne Université, Paris, France.
  • Svetel M; Institut du Cerveau et de la Moelle épinière, ICM, Inserm, CNRS, Sorbonne Université, Paris, France.
  • Samanci B; Department of Real-World evidence studies, CENTOGENE GmbH, Rostock, Germany.
  • Hanagasi HA; Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom.
  • Bilgiç B; Department of Medical Genetics, CENTOGENE GmbH, Rostock, Germany.
  • Obeso JA; Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.
  • Kurtis MM; Movement Disorders Department, Neurology Clinic, University Clinical Center of Serbia, Belgrade, Serbia.
  • Cogan G; Behavioral Neurology and Movement Disorders Unit, Department of Neurology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
  • Basak AN; Behavioral Neurology and Movement Disorders Unit, Department of Neurology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
  • Kiziltan G; Behavioral Neurology and Movement Disorders Unit, Department of Neurology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
  • Gül T; CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, Madrid, Spain.
  • Yalçin G; HM CINAC, Hospital Universitario HM Puerta del Sur, HM Hospitales, Madrid, Spain.
  • Elibol B; University CEU-San Pablo, Madrid, Spain.
  • Barisic N; Neurology Department, Hospital Ruber Internacional, Madrid, Spain.
  • Ng EW; Institut du Cerveau et de la Moelle épinière, ICM, Inserm, CNRS, Sorbonne Université, Paris, France.
  • Fan SS; Koç University, School of Medicine, Research Center for Translational Medicine KUTTAM-Neurodegeneration Research Laboratory NDAL, Istanbul, Turkey.
  • Hershkovitz T; Department of Neurology, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey.
medRxiv ; 2024 Jun 20.
Article em En | MEDLINE | ID: mdl-39148840
ABSTRACT
Dissecting biological pathways highlighted by Mendelian gene discovery has provided critical insights into the pathogenesis of Parkinson's disease (PD) and neurodegeneration. This approach ultimately catalyzes the identification of potential biomarkers and therapeutic targets. Here, we identify PSMF1 as a new gene implicated in PD and childhood neurodegeneration. We find that biallelic PSMF1 missense and loss-of-function variants co-segregate with phenotypes from early-onset PD and parkinsonism to perinatal lethality with neurological manifestations across 15 unrelated pedigrees with 22 affected subjects, showing clear genotype-phenotype correlation. PSMF1 encodes the proteasome regulator PSMF1/PI31, a highly conserved, ubiquitously expressed partner of the 20S proteasome and neurodegeneration-associated F-box-O 7 and valosin-containing proteins. We demonstrate that PSMF1 variants impair mitochondrial membrane potential, dynamics and mitophagy in patient-derived fibroblasts. Additionally, we develop models of psmf1 knockdown Drosophila and Psmf1 conditional knockout mouse exhibiting age-dependent motor impairment, with diffuse gliosis in mice. These findings unequivocally link defective PSMF1 to early-onset PD and neurodegeneration and suggest mitochondrial dysfunction as a mechanistic contributor.

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: MedRxiv Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Reino Unido País de publicação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: MedRxiv Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Reino Unido País de publicação: Estados Unidos